Integra LifeSciences earnings swing and guidance reset

Integra LifeSciences Holdings (IART) has moved from a prior year net loss to a modest profit and paired that with fresh third quarter and full year 2026 revenue guidance.

The company reported second quarter 2026 sales of US$418.76 million compared with US$415.61 million a year earlier, with net income of US$4.48 million replacing a prior year net loss of US$484.07 million.

Integra LifeSciences Holdings’ latest guidance reset and return to profit sit against a mixed market track record, with the share price up 48.9% year to date and the 1 year total shareholder return at 40.5%, but the 3 year and 5 year total shareholder returns down 60.0% and 74.3%. The 7.4% 1 day share price return after the earnings release, alongside a 27.7% 90 day share price return, suggests investors are reassessing the company’s earnings risk after prior setbacks, even though longer term holders have seen sizeable declines.

If Integra LifeSciences has you looking more closely at medical technology, it could be worth seeing which other healthcare companies are attracting attention through our 41 healthcare AI stocks

Integra LifeSciences has swung back to profit and the share price has rebounded sharply, while long term returns are still deeply negative. Is this latest move mainly about improving fundamentals, or a reset in sentiment that leaves the stock mispriced?

Most Popular Narrative: 33.8% Undervalued

At a last close of $17.88, Integra LifeSciences sits well below a most-followed fair value estimate of $27.00, which frames the latest rebound in a different light.

With the global population aging and chronic disease prevalence increasing, Integra's leadership in advanced wound care and tissue technology positions it to benefit disproportionately from sustained volume growth and pricing power, fueling robust multi-year revenue and market share gains.

Curious what underpins that $27.00 fair value for Integra LifeSciences. The narrative focuses on steadier revenue progress, recovering margins, and a future earnings multiple that remains below the broader medical equipment group.

Result: Fair Value of $27.00 (UNDERVALUED)

However, Integra LifeSciences still faces meaningful regulatory and quality risks, along with pricing pressure in wound care, which could quickly undermine the upbeat valuation narrative.

Next Steps

With Integra LifeSciences showing both renewed momentum and ongoing questions, now is a good time to review the numbers yourself and pressure test the story. To weigh up both sides of the argument, start by checking the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Integra LifeSciences?

If Integra LifeSciences has sharpened your focus, do not stop here. Broadening your watchlist with fresh ideas can help you stress test your portfolio thinking.

• Spot potential bargains early by scanning for quality companies that look mispriced using the 53 high quality undervalued stocks.
• Prioritise resilience by checking companies with stronger finances through the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for less crowded opportunities that still show strong fundamentals with the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.